Biotricity, Inc. BTCY

Company Overview

Biotricity, Inc. (NASDAQ: BTCY) is a medical technology and remote patient monitoring company focused on cardiovascular diagnostics, chronic care management, and connected healthcare solutions. The company operates within the digital health, cardiac monitoring, and medical device industries, developing FDA-cleared technologies that enable physicians to remotely monitor patients with cardiac and other chronic conditions. Its business model combines proprietary hardware, cloud-based software, analytics, and recurring monitoring services intended to support early diagnosis and long-term patient management.

The company’s primary revenue drivers include its remote cardiac monitoring ecosystem, diagnostic services, and subscription-based monitoring platforms. Key products include Bioflux, a mobile cardiac telemetry solution; Biotres, a three-channel wearable cardiac monitoring device; and Biocare Cardiac, a clinical monitoring platform. Biotricity primarily serves physicians, cardiology practices, diagnostic testing providers, healthcare systems, and ambulatory monitoring markets in the United States. The company was founded in 2012 and evolved from a consumer-focused biometric concept into a clinically oriented cardiac diagnostics and remote healthcare platform emphasizing continuous monitoring, data integration, and preventative care.

Business Operations

Biotricity generates revenue through device sales, technology-enabled diagnostic services, and recurring monitoring contracts tied to remote cardiac care. Its core operating activities center on cardiac diagnostics and remote patient monitoring through integrated hardware and software platforms. The company’s principal business units include its cardiac monitoring technologies and connected healthcare services built around Bioflux, Biotres, and related cloud infrastructure. Revenue is derived from physician utilization, reimbursement-supported monitoring services, and ongoing patient management programs.

Operations are concentrated primarily in the United States, where the company maintains regulatory clearances and commercial relationships with healthcare providers and diagnostic networks. Biotricity controls proprietary software platforms, wearable biosensor technologies, data analytics systems, and cloud-based patient management infrastructure. The company has also expanded through healthcare distribution relationships and reimbursement-driven clinical service models designed to integrate with physician workflows and electronic healthcare systems. Public filings indicate a strategic emphasis on scalable SaaS-enabled healthcare delivery and recurring monitoring utilization rather than one-time hardware sales.

Strategic Position & Investments

Biotricity’s strategic direction focuses on expanding remote diagnostics, preventative cardiac care, and chronic disease management through connected medical technologies. The company has invested in FDA-cleared wearable monitoring devices, AI-supported analytics capabilities, and integrated digital healthcare platforms intended to improve patient compliance and physician decision-making. Management has emphasized expanding reimbursement-supported services and increasing adoption among cardiology practices and outpatient monitoring providers.

The company has pursued product expansion through internal development and commercialization initiatives rather than large-scale acquisitions. Strategic growth efforts have included broader deployment of Biocare Telemed, enhancement of diagnostic reporting capabilities, and expansion into consumer-oriented healthcare engagement technologies linked to chronic disease monitoring. Biotricity’s positioning is differentiated by its integrated ecosystem combining wearable devices, cloud software, analytics, and diagnostic services within a unified remote cardiac monitoring framework. Public disclosures indicate continued focus on remote healthcare infrastructure, digital diagnostics, and scalable connected-care technologies.

Geographic Footprint

Biotricity is headquartered in Redwood City, California, and maintains its primary commercial and operational focus in the United States healthcare market. Its products and monitoring services are designed principally for U.S.-based physicians, healthcare systems, ambulatory monitoring providers, and cardiology practices operating within American reimbursement and regulatory frameworks.

While the company has historically referenced broader North American and international technology capabilities, publicly verifiable commercial operations remain concentrated in the U.S. market. Biotricity’s strategic influence is tied more to digital healthcare scalability and cloud-enabled monitoring infrastructure than to extensive international physical operations. Data regarding material international operating segments or significant overseas revenue contributions is inconclusive based on available public sources.

Leadership & Governance

Biotricity was founded by Waqaas Al-Siddiq, who has remained a central figure in the company’s strategic development and commercialization efforts. Leadership has consistently emphasized preventative healthcare, continuous biometric monitoring, and the transition from episodic care toward data-driven remote patient management. Public communications and regulatory filings describe a strategy centered on integrating medical-grade diagnostics with consumer-friendly wearable technologies and recurring digital healthcare services.

Key executives and leadership personnel include:

• Waqaas Al-Siddiq – Founder, Chairman, and Chief Executive Officer
• John Benson – Chief Financial Officer
• Joseph Capper – Chief Operating Officer
• Robert Saltzstein – Chief Medical Officer

The company operates under a publicly traded governance structure and files regular disclosures through SEC filings, including annual reports, quarterly reports, and investor presentations outlining operational performance, regulatory developments, and strategic priorities.